Hi All,
A new proposed OHDSI study protocol has been posted on the Wiki and on GitHub.
The objective of this study is to derive incident medication-use data that large healthcare organizations can combine with data on adverse event risks and costs to conduct cost-effectiveness / cost-benefit analyses for the purpose of justifying pre-emptive pharmacogenomics testing.
Please provide any comments or suggestions over the next 2 weeks. If you would like to join as a contributing investigator, contributing to the analysis and write-up of this work, please let me know. ( Patrick Ryan, Jon Duke, George Hripcsak, Abraham G. Hartzema, Christian Reich you have been added based on our previous discussion.)
The commenting period will close on 4/8/2015.
Thanks,
Rich